Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Adicet Bio is raising $80,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Aya Jakobovits played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Adicet Bio

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs).

To learn more about Adicet Bio, visit http://www.adicetbio.com/

Contact:
Aya Jakobovits, Chief Executive Officer
650-542-0034
ajakobovits@adicetbio.com
https://www.linkedin.com/in/aya-jakobovits-871b5110/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved